Laurie H. Sehn, MD
Articles
Laurie H. Sehn, MD, on the Key Takeaways From the GO29365 Study in DLBCL
December 31st 2020The preliminary findings of the extension arm of the phase 1b/2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma.
Laurie H. Sehn, MD, on the Impact of Additional Findings From the GO29365 Study in DLBCL
December 24th 2020Extended follow up and preliminary findings from an extension cohort of the GO29365 study of polatuzumab vedotin (Polivy) for patients with diffuse large B-cell lymphoma confirmed earlier reports of efficacy and safety, and demonstrated continued deepening responses.
Laurie H. Sehn, MD, Discusses Preliminary Findings From the GO29365 Study in DLBCL
December 8th 2020The preliminary findings of the extension arm of the phase 2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin (Polivy) plus bendamustine (Bendeka) and rituximab (Rituxan) for patients with diffuse large B cell lymphoma.
